Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Wen Li

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Neuropharmacology|June 18, 2013
NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim testSnjezana Lelas, Yu-Wen Li, Tanya L Wallace-Boone, et al.
Journal of Medicinal Chemistry|October 29, 2004
Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonistsCarolyn D Dzierba, Amy G Takvorian, Maria Rafalski, et al.
Neuropharmacology|November 3, 2015
Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancyYu-Wen Li, Matthew A Seager, Trevor Wojcik, et al.
Pharmacology, Biochemistry, and Behavior|September 16, 2017
Characterization of the adrenocorticotrophic hormone - induced mouse model of resistance to antidepressant drug treatmentBettadapura N Srikumar, Mahesh Paschapur, Narasimharaju Kalidindi, et al.
Nuclear Medicine and Biology|May 6, 2014
Synthesis and evaluation of candidate PET radioligands for corticotropin-releasing factor type-1 receptorsNicholas J Lodge, Yu-Wen Li, Frederick T Chin, et al.
Bioorganic & Medicinal Chemistry Letters|June 7, 2015
Biaryls as potent, tunable dual neurokinin 1 receptor antagonists and serotonin transporter inhibitorsAndrew P Degnan, George O Tora, Ying Han, et al.
Journal of Psychopharmacology (Oxford, England)|November 29, 2018
Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupusBettadapura N Srikumar, Pattipati S Naidu, Narasimharaju Kalidindi, et al.
Journal of Medicinal Chemistry|April 14, 2009
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Liqi He, Todd Clarke, et al.
Journal of Medicinal Chemistry|April 14, 2009
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Todd Clarke, Liqi He, et al.
Bioorganic & Medicinal Chemistry Letters|December 21, 2012
Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depressionKevin W Gillman, Michael F Parker, Mark Silva, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Neuropharmacology|June 18, 2013
NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim testSnjezana Lelas, Yu-Wen Li, Tanya L Wallace-Boone, et al.
Journal of Medicinal Chemistry|October 29, 2004
Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonistsCarolyn D Dzierba, Amy G Takvorian, Maria Rafalski, et al.
Neuropharmacology|November 3, 2015
Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancyYu-Wen Li, Matthew A Seager, Trevor Wojcik, et al.
Pharmacology, Biochemistry, and Behavior|September 16, 2017
Characterization of the adrenocorticotrophic hormone - induced mouse model of resistance to antidepressant drug treatmentBettadapura N Srikumar, Mahesh Paschapur, Narasimharaju Kalidindi, et al.
Nuclear Medicine and Biology|May 6, 2014
Synthesis and evaluation of candidate PET radioligands for corticotropin-releasing factor type-1 receptorsNicholas J Lodge, Yu-Wen Li, Frederick T Chin, et al.
Bioorganic & Medicinal Chemistry Letters|June 7, 2015
Biaryls as potent, tunable dual neurokinin 1 receptor antagonists and serotonin transporter inhibitorsAndrew P Degnan, George O Tora, Ying Han, et al.
Journal of Psychopharmacology (Oxford, England)|November 29, 2018
Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupusBettadapura N Srikumar, Pattipati S Naidu, Narasimharaju Kalidindi, et al.
Journal of Medicinal Chemistry|April 14, 2009
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Liqi He, Todd Clarke, et al.
Journal of Medicinal Chemistry|April 14, 2009
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Todd Clarke, Liqi He, et al.
Bioorganic & Medicinal Chemistry Letters|December 21, 2012
Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depressionKevin W Gillman, Michael F Parker, Mark Silva, et al.
Pageof 8